Do these CVI-related skin conditions look familiar?



Distinct skin conditions that require gentle, effective care.

Chronic venous insufficiency (CVI) and venous leg ulcers (VLUs) can significantly diminish comfort, mobility, and quality of life (QoL), and while compression therapy is the gold standard, discomfort and itch often limit patient compliance. Backed by real-world evidence from the **APRICOT** and **PEACH** studies, CoFlex® TLC Calamine delivers proven comfort, reliable performance, and ease of use—supporting confident clinical choice across both full-strength ("Standard") and reduced ("Lite") compression pathways.



SUPPORTS IMPROVED QoL

- Symptom relief → Promotes mobility & daily function → Improved well-being

COMFORT ADVANTAGE

- Patients preferred **4:1** over Standard of Care

HEALING PERFORMANCE

- Equivalent healing outcomes validated in peer-reviewed data

CLINICIAN-FRIENDLY APPLICATION

- Visual indicators for application, EasyTear technology, self-adhering design

Ovik HEALTH

CoFlex® TLC Calamine

Comfort Patients Prefer. Compression Clinicians Trust.

APRICOT Trial	PEACH Trial
Randomized, open-label, multicenter crossover trial	Pragmatic, randomized, controlled trial
CVI requiring compression	Venous or mixed-etiology leg ulcers
N=35	N=77
Primary Endpoint: Severity of Prurtitis (SPS)	Primary Endpoint: Wound healed at 12 weeks
Secondary Endpoints: Visual Pruritis Scale, 5-D Itch, CIVIQ-20, VCSS, PUSH, Patient Feedback Surveys, Safety	Secondary Endpoints: Wound Status at 6-weeks, PUSH, EQ-5D-5L, VEINES-Sym, Safety
Standard and Lite compression	Lite compression

Patients consistently preferred CoFlex TLC Calamine for comfort, an essential factor that impacts compliance and longer-term therapeutic success

CoFlex TLC Calamine Lite performs equivalently to Standard of Care (SOC) in healing outcomes, allowing clinicians to choose based on comfort, preference, and workflow


Patients found CoFlex TLC Calamine:

4:1 preferred and would recommend

5:1 more comfortable to the skin

7:1 easier to move in

12-Week Healing Rates



SCAN TO LEARN MORE
AND READ THE FULL APRICOT AND PEACH CLINICAL STUDIES



Baseline



Healed 6 weeks

CITATION / FOOTNOTES

1. Jonker L, Todhunter J, Robinson L, Fisher S. Open-label, randomised, multicenter crossover trial assessing two-layer compression bandaging for chronic venous insufficiency: results of the APRICOT trial. *Br J Community Nurs*. 2020 Jun 2;25(Sup6):S6-S13. doi: 10.12968/bjcn.2020.25.Sup6.S6. PMID: 32501761.
2. Todhunter J, Greenhow H, Jonker L. Comparison of 'Lite' reduced compression two-layer bandages for treatment of leg ulcers: Results of the pragmatic, single-centre randomized controlled PEACH trial. *Journal of Vascular Nursing.* 2025. doi: 10.1016/j.jnn.2025.07.004

*CoFlex® TLC is the equivalent to AndoFlex® TLC in the United Kingdom.
Standard of Care (SOC) in APRICOT and PEACH trials: Coban2 and Coban2 Lite (Solventum, Eagan, MN, USA)
Clinical images provided in courtesy by Dr. Leon Jonker (PhD) and Jane Todhunter (RNN) at North Cumbria Integrated Care NHS FT

©2026 OVIK Health, LLC. All rights reserved.